June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Foveal thickness fluctuation on visual and morphologic outcomes in anti-vascular endothelial growth factor treatments for branch retinal vein occlusion
Author Affiliations & Notes
  • Daisuke Nagasato
    Tsukazaki Byoin, Himeji, Hyogo, Japan
  • Yuki Muraoka
    Ophthalmology, DepartmentKyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan
  • Mao Tanabe
    Tsukazaki Byoin, Himeji, Hyogo, Japan
  • Naomi Nishigori
    Ophthalmology, DepartmentKyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan
  • Rie Osaka
    Kagawa Daigaku Igakubu Daigakuin Igakukei Kenkyuka, Kita-gun, Kagawa, Japan
  • Yoshinori Mitamura
    Tokushima Daigaku Byoin, Tokushima, Tokushima, Japan
  • Hitoshi Tabuchi
    Tsukazaki Byoin, Himeji, Hyogo, Japan
  • Shin Kadomoto
    Ophthalmology, DepartmentKyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan
  • Tomoaki Murakami
    Ophthalmology, DepartmentKyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan
  • Sotaro Ooto
    Ophthalmology, DepartmentKyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan
  • Kiyoshi Suzuma
    Kagawa Daigaku Igakubu Daigakuin Igakukei Kenkyuka, Kita-gun, Kagawa, Japan
  • Akitaka Tsujikawa
    Ophthalmology, DepartmentKyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan
  • Footnotes
    Commercial Relationships   Daisuke Nagasato None; Yuki Muraoka Bayer, Code R (Recipient), Novartis Pharma K.K., Code R (Recipient), Senju, Code R (Recipient), Nidek, Code R (Recipient); Mao Tanabe None; Naomi Nishigori None; Rie Osaka None; Yoshinori Mitamura None; Hitoshi Tabuchi None; Shin Kadomoto Nidek, Canon, Code R (Recipient); Tomoaki Murakami Novartis Pharma K.K., Bayer, Santen, Senju, Code R (Recipient); Sotaro Ooto Novartis Pharma K.K., Bayer, Santen, Senju, Code R (Recipient); Kiyoshi Suzuma Pfizer, Novartis Pharma K.K., Bayer, Alcon, Santen, Senju, Kowa, Hoya, AMO Japan, Code F (Financial Support), Novartis Pharma K.K., Bayer, Alcon, Santen, Senju, Kowa, Hoya, Code R (Recipient); Akitaka Tsujikawa Pfizer, Novartis Pharma K.K., Bayer, Alcon, Santen, Senju, Kowa, Hoya, AMO Japan, Code F (Financial Support), Pfizer, Novartis Pharma K.K., Bayer, Alcon, Santen, Senju, Nidek, Kowa, Hoya, AMO Japan, Code R (Recipient)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1734 – F0194. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daisuke Nagasato, Yuki Muraoka, Mao Tanabe, Naomi Nishigori, Rie Osaka, Yoshinori Mitamura, Hitoshi Tabuchi, Shin Kadomoto, Tomoaki Murakami, Sotaro Ooto, Kiyoshi Suzuma, Akitaka Tsujikawa; Foveal thickness fluctuation on visual and morphologic outcomes in anti-vascular endothelial growth factor treatments for branch retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1734 – F0194.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To examine the effects of foveal thickness (FT) fluctuation (FTF) of visual and morphologic outcomes in anti-vascular endothelial growth factor (VEGF) treatments with pro re nata regimen for Branch retinal vein occlusion (BRVO)- macular edema (ME).

Methods : We conducted a retrospective, observational case series (2012-2021) at a multi-center retinal practice among 309 treatment-naïve patients (309 eyes) with BRVO. FT was assessed via optical coherence tomography (OCT) at each study visit. We evaluated the logarithm of the minimal angle of resolution best corrected visual acuity (logMAR BCVA) and the defect length of the foveal ellipsoid zone (EZ) band measured via OCT.

Results : At baseline, the mean logMAR BCVA was 0.30±0.30 and the mean FT was 503±162 µm. The number of anti-VEGF injections for BRVO-ME was 5.8±4.6 during the mean follow-up period (50.6±22.2 months). At the final examination, the mean logMAR BCVA and FT values were significantly improved compared with the baseline. Multiple regression analyses showed that age, baseline logMAR BCVA, and FTF were significantly associated with the final logMAR BCVA (β=0.20, 0.35, and 0.30, respectively). FTF (divided into Groups 0-3 in ascending order of FTF) was significantly associated with the logMAR BCVA and the defect length of the foveal EZ band at the final examination. The defect lengths of the foveal EZ band were longitudinally shortened in Groups 0-1 and were slightly prolonged in Groups 2-3. The logMAR BCVA maintained improvements in Groups 0-1, and worsened slightly in Groups 2-3.

Conclusions : FTF was significantly associated with visual acuity and foveal photoreceptor status. Thus, we conclude that morphologic and functional prognoses of eyes with BRVO may be improved by identifying the characteristics of eyes with a larger FTF and consequently controlling the FTF more strictly.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×